Company overview
Arima Genomics provides Hi-C technology and end-to-end solutions for 3D genomic analysis, enabling discovery of biomarkers and therapies in human health, cancer diagnostics, and epigenetics. Their assays capture long-range chromatin interactions, including compartments, TADs, and loops, with user-friendly workflows compatible with standard NGS protocols and low-input DNA options. Partnerships like with Fox Chase Cancer Center integrate their Aventa tests into clinical protocols for lymphoma and sarcoma.
Arima Genomics is listed in the NovaPharmaNews Supplier Hub as a Diagnostics & Testing partner serving United States & Americas. Core focus areas include 3d genomics, hi-c technology, cancer diagnostics, chromatin interactions, epigenetics research.
Industry categories: Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with Arima Genomics include Diagnostic — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://arimagenomics.com
- Categories
- Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- 3d genomics, hi-c technology, cancer diagnostics, chromatin interactions, epigenetics research
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What Hi-C technologies does Arima Genomics offer for pharma R&D?
- Arima offers robust Hi-C kits and workflows for genome-wide or targeted 3D genomics, including Arima-HiC, single-cell 3C kits, and Aventa tests for cancer diagnostics, with flexible sample requirements and integration with NGS.
- What are the key applications in human health and cancer?
- Applications focus on redefining cancer diagnostics via whole-genome 3D structure, improving chromatin loop detection, and enabling therapy selection insights, as used in partnerships with Fox Chase for lymphoma and sarcoma testing.
- What are the workflow capabilities and timelines?
- Workflows are user-friendly, taking as little as 6 hours from sample to discovery, with end-to-end solutions, low sequencing depths, and compatibility across organisms for epigenetics and structural variation studies.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
